Clinical Pharmacokinetics of Metoclopramide

SummaryMetoclopramide is rapidly and well absorbed from the gastrointestinal tract, and in man undergoes variable first-pass metabolism (oral bioavailability 32 to 100%). In man, N-4 sulphate conjugation is an important pathway of metabolism and after oral administration the ratio of free to conjugated metoclopramide in urine correlates with the plasma AUC.The elimination half-life of metoclopramide is dose-dependent after both intravenous and oral administration of single doses between 5 and 20mg. Metabolic profiles in animal species studied are very different from man. The clearance of metoclopramide is reduced in patients with renal failure to approximately 50% of normals and the terminal half-life is prolonged; this is despite the fact that renal clearance of free drug accounts for only 20% of the administered dose in normals.Preliminary studies after ‘high dose’ metoclopramide demonstrate accumulation to high plasma concentrations with linear kinetics, suggesting that current high dose regimens are unnecessarily cumbersome.

[1]  C. McArdle,et al.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. , 1979, British medical journal.

[2]  J. Segura,et al.  The absorption and elimination of metoclopramide in three animal species , 1976, The Journal of pharmacy and pharmacology.

[3]  Y. Tam,et al.  Modification of metoclopramide GLC assay: application to human biological specimens. , 1979, Journal of pharmaceutical sciences.

[4]  D. Cowan,et al.  Identification of four new metabolic products of metoclopramide using mass spectrometry. , 1976, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  D. Bateman,et al.  Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. , 1978, British journal of clinical pharmacology.

[6]  A. Hay Pharmacological analysis of the effects of metoclopramide on the guinea pig isolated stomach. , 1977, Gastroenterology.

[7]  J. Jaeken,et al.  Dystonic Reactions in Children Caused by Metoclopramide , 1970, Archives of disease in childhood.

[8]  R. N. Brogden,et al.  Metoclopramide. An updated review of its pharmacological properties and clinical use. , 1983, Drugs.

[9]  C. Moertel,et al.  Controlled clinical studies of orally administered antiemetic drugs. , 1969, Gastroenterology.

[10]  N. Legg,et al.  Metoclopramide in Parkinson's disease , 1978, Clinical pharmacology and therapeutics.

[11]  A. Caralps METOCLOPRAMIDE AND RENAL FAILURE , 1979, The Lancet.

[12]  T. Arita,et al.  Transformation and excretion of drugs in biological systems. IV. Reabsorption of biliary metoclopramide-N4-glucuronide and -N4-sulfonate from rabbit intestine. , 1970, Chemical & pharmaceutical bulletin.

[13]  R. B. Bruce,et al.  Metoclopramide metabolism and determination by high-pressure liquid chromatography. , 1977, Journal of pharmaceutical sciences.

[14]  K. Schulze-Delrieu Drug therapy. Metoclopramide. , 1981, The New England journal of medicine.

[15]  T. Arita,et al.  Transformation and excretion of drugs in biological systems. II. Transformation of metoclopramide in rabbits. , 1970, Chemical & pharmaceutical bulletin.

[16]  D. Bateman,et al.  High dose metoclopramide-preliminary pharmacokinetic studies. , 1983, British journal of clinical pharmacology.

[17]  D. Bateman,et al.  Concentration effect studies with oral metoclopramide. , 1979, British journal of clinical pharmacology.

[18]  R. Kapil,et al.  The pharmacokinetics of metoclopramide in rats with experimental renal and hepatic dysfunction. , 1981, The Journal of pharmacology and experimental therapeutics.

[19]  D. Bateman,et al.  PHARMACOKINETICS OF METOCLOPRAMIDE , 1979, The Lancet.

[20]  R. Opfell,et al.  Intravenous Metoclopramide: An Effective Antiemetic in Cancer Chemotherapy , 1982 .

[21]  T. Arita,et al.  Transformation and excretion of drugs in biological systems. 3. Separatory determination of metoclopramide and its N4-glucuronide and N4-sulfonate in rabbit urine and bile. , 1970, Chemical & pharmaceutical bulletin.

[22]  R. Gralla,et al.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. , 1981, The New England journal of medicine.

[23]  J. Virjee,et al.  The effect of hyoscine butylbromide on the swallowing of capsules. , 1983, British journal of clinical pharmacology.

[24]  Y. Tam,et al.  Dose-dependent pharmacokinetics of metoclopramide in rat: an effect of hemoperfusion? , 1981, The Journal of pharmacology and experimental therapeutics.

[25]  D. Bateman,et al.  The pharmacokinetics of metoclopramide in man with observations in the dog. , 1980, British journal of clinical pharmacology.

[26]  E. Melamed,et al.  Tardive dyskinesia associated with metoclopramide. , 1978, British medical journal.

[27]  A. Pingoud,et al.  The pharmacokinetics, bioequivalence and bioavailability of different formulations of metoclopramide in man. , 1981, Arzneimittel-Forschung.

[28]  P. Lundborg,et al.  Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. , 1979, British journal of clinical pharmacology.